S-1/A: Drugs Made In America II Corp. Files $500M SPAC IPO

Drugs Made In America Acquisition II Corp., a blank check company, filed an S-1/A for a $500 million initial public offering to target businesses in the pharmaceutical industry.

Summary

• Drugs Made In America Acquisition II Corp. is a newly incorporated blank check company in the Cayman Islands, aiming to effect a business combination primarily within the pharmaceutical industry.
• The company is offering 50,000,000 units at $10.00 per unit, totaling $500,000,000. Each unit comprises one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon consummation of an initial business combination.
• Underwriters have a 45-day option to purchase up to an additional 7,500,000 units.
• The sponsor, Drugs Made In America Acquisition II LLC, and Cantor Fitzgerald & Co. will purchase an aggregate of 1,200,000 private units at $10.00 per unit, totaling $12,000,000.
• A total of $500,000,000 (or $575,000,000 if the over-allotment option is fully exercised) will be deposited into a U.S.-based trust account, to be invested in U.S. government treasury obligations or money market funds.
• The company has 24 months from the closing of the offering to complete an initial business combination. Failure to do so will result in the redemption of public shares at approximately $10.00 per share, with rights expiring worthless.
• Public shareholders will experience immediate and substantial dilution of approximately 112.40% (or $11.24 per share, assuming no over-allotment and maximum redemption) due to the sponsor's nominal purchase price of $0.0024 per founder share.
• The management team, led by CEO Lynn Stockwell and CFO Glenn Worman, intends to focus on mitigating U.S. medical supply chain risks through on-shoring advanced domestic manufacturing for critical drugs, targeting an estimated $44 billion market segment.
• As of June 30, 2025, the company reported a net loss of $(97,400) for the six months ended, total assets of $113,395, total liabilities of $327,514, and a shareholders deficit of $(214,119).

Sentiment

Score: 6

Explanation: The company presents a clear strategic focus and an experienced management team for its SPAC. However, it carries the inherent risks of a blank check company, including significant dilution for public shareholders, potential conflicts of interest due to management's involvement in another SPAC, and the uncertainty of finding a suitable acquisition target within the specified timeframe. The financial position is a deficit prior to the IPO.

Positives

• The management team possesses extensive experience and a broad network within the pharmaceutical industry, which is expected to aid in identifying suitable acquisition targets.
• The company has a clear strategic focus on addressing critical U.S. medical supply chain vulnerabilities by promoting domestic manufacturing of pharmaceuticals and active pharmaceutical ingredients (APIs).
• The business model aims for a fully integrated, competitive cost structure from plant-based raw materials to finished generic drugs, potentially disrupting the current market.
• The target market for plant-based production, API, and generic medications is estimated at $44 billion, indicating significant growth potential.
• Commitment to leveraging advanced technology, including artificial intelligence, in controlled and energy-efficient production environments.
• The company plans to establish robust corporate governance with independent directors on the audit and compensation committees, and will adopt a Code of Conduct and compensation recovery policy.

Negatives

• The company is a blank check company with no operating history, revenues, or identified target business, presenting a highly speculative investment.
• Public shareholders will face immediate and substantial dilution, estimated at 112.40% or $11.24 per share, due to the sponsor's acquisition of founder shares at a nominal price.
• Significant conflicts of interest exist as the company's officers and directors also serve another SPAC (Drugs Made In America Acquisition Corp. DMAA) and have pre-existing fiduciary obligations to present business opportunities to DMAA first.
• There is a risk of not completing a business combination within the 24-month completion window, which would lead to the liquidation of the trust account and public shareholders' rights expiring worthless.
• Public shareholders may have limited influence on the approval of a business combination, as founder shares will vote in favor, and only 4.5% of public shares are needed for approval under certain quorum assumptions.
• The ability of public shareholders to redeem shares could make the company less attractive to potential target businesses or hinder the completion of the most desirable transactions.
• The market for directors and officers liability insurance has become more difficult and expensive for SPACs, potentially increasing costs and complexity for a business combination.
• The company may be subject to a 1% U.S. federal excise tax on redemptions if it domesticates in connection with a business combination, which would reduce cash available for redemptions or the target business.
• There is a risk of substantial write-downs, write-offs, or other charges post-business combination if due diligence fails to identify material issues or unexpected factors arise.
• Proceeds in the trust account are subject to claims from creditors, which could reduce the per-share redemption amount to less than $10.00.
• The securities in the trust account could bear negative interest rates, further reducing the redemption amount for public shareholders.
• Shareholders may be held liable for claims by third parties against the company to the extent of distributions received upon redemption.
• The company may be deemed a Passive Foreign Investment Company (PFIC), leading to adverse U.S. federal income tax consequences for U.S. Holders.
• The share price of the combined company may decline after the initial business combination, potentially below the initial offering price of the units.
• The business combination and subsequent structure may not be tax-efficient for shareholders and rights holders, potentially triggering taxable income without cash distributions.

Risks

• The company is a newly incorporated exempted company with no operating history, no revenues, and no identified operating business as a target, providing no basis to evaluate its ability to achieve its business objective.
• Public shareholders may not be afforded an opportunity to vote on the proposed business combination, and even if a vote is held, founder shares will participate, meaning a combination could be completed without majority public shareholder support (only 4.5% of public shares needed for approval under minimum quorum).
• The ability of public shareholders to exercise redemption rights with a large number of shares may make the company's financial condition unattractive to potential targets, potentially preventing the completion of desirable business combinations.
• The 24-month completion window may give potential target businesses leverage in negotiations and limit due diligence time, potentially undermining the ability to complete a business combination on favorable terms.
• Global health crises (e.g., COVID-19) and geopolitical conflicts (e.g., Russia-Ukraine, Middle East) could materially adversely affect the search for a business combination and the operations of any target business.
• As a Cayman Islands incorporated company, investors may face difficulties in protecting their interests, and their ability to protect rights through U.S. Federal or state courts may be limited.
• Increased competition from other SPACs and investment entities for attractive targets may increase acquisition costs or result in an inability to find a suitable target.
• Changes in the market for directors and officers liability insurance could make it more difficult and expensive to negotiate and complete an initial business combination.
• Underwriters are entitled to deferred underwriting commissions upon completion of a business combination, which may create conflicts of interest in their advisory roles.
• Failure to complete an initial business combination within the 24-month completion window will result in liquidation, public shareholders receiving approximately $10.00 per share (or less in certain circumstances), and rights expiring worthless.
• Initial shareholders, advisors, or affiliates may purchase shares or rights from public shareholders, potentially influencing a vote on a proposed business combination and reducing the public float.
• The company may enter into a business combination with a target that does not fully meet its identified investment criteria and guidelines.
• Acquisition opportunities may involve early-stage, financially unstable businesses or entities lacking established revenue or earnings records.
• The company is not required to obtain an independent fairness opinion for non-affiliated business combinations, requiring shareholders to rely on the board's judgment.
• Resources could be wasted on researching uncompleted acquisitions, adversely affecting subsequent search efforts.
• Uncertainty regarding the merits or risks of any particular target business's operations due to the broad search criteria.
• Shareholders may fail to receive notice of redemption offers or comply with tendering procedures, leading to unredeemed shares.
• Shareholders have no rights or interests in trust account funds except under limited circumstances, potentially forcing them to sell shares/rights at a loss to liquidate their investment.
• Nasdaq may delist the company's securities, limiting liquidity and trading ability.
• Investors will not be entitled to certain protections afforded to investors in Rule 419 blank check offerings.
• The company may not hold an annual general meeting until after the initial business combination, delaying the opportunity for shareholders to appoint directors.
• Insufficient funds outside the trust account to operate until the end of the completion window may hinder the ability to complete a business combination.
• Past performance by the management team is not indicative of future performance.
• The company may seek acquisition targets outside of management's areas of expertise.
• Subsequent to a business combination, the company may be required to take write-downs or write-offs, restructuring, and impairment or other charges.
• If third parties bring claims against the company, the proceeds held in the trust account could be reduced, leading to a per-share redemption amount less than $10.00.
• The securities in which trust account funds are invested could bear a negative rate of interest, reducing the value of assets in trust.
• If the company files for bankruptcy or winding-up, a court may seek to recover distributions received by shareholders, and directors may be viewed as having breached fiduciary duties.
• If the company is deemed an investment company under the Investment Company Act, it may face burdensome compliance requirements and restricted activities.
• The grant of registration rights to security holders may make it more difficult to complete an initial business combination and adversely affect the market price of ordinary shares.
• Issuance of additional shares to complete a business combination or under an employee incentive plan could dilute existing shareholders.
• Because each unit contains one right to receive one-tenth (1/10) of an ordinary share, units may be worth less than those of other SPACs.
• The terms of the rights may be amended in a manner adverse to holders with the approval of a majority of outstanding public rights.
• The rights agreement designates New York courts as the sole and exclusive forum for certain actions, potentially limiting rights holders' ability to obtain a favorable judicial forum.
• Provisions in the amended and restated memorandum and articles of association may inhibit a takeover.
• The Cayman Islands courts are unlikely to recognize or enforce U.S. judgments based on certain civil liability provisions of U.S. securities laws.
• The requirement to furnish target business financial statements may limit the pool of potential targets.
• Reliance on emerging growth company and smaller reporting company exemptions may make securities less attractive to investors and comparisons difficult.
• Compliance obligations under the Sarbanes-Oxley Act may make it more difficult to effectuate a business combination and increase costs.
• Pursuing a target with operations outside the United States would expose the company to additional cross-border business risks.
• Management unfamiliarity with U.S. securities laws post-business combination could lead to regulatory issues.
• Uncertain or adverse U.S. federal income tax consequences for investors.
• The business combination and the company's structure thereafter may not be tax-efficient to shareholders and rights holders.
• Reincorporation or transfer to another jurisdiction may result in taxes imposed on shareholders or rights holders.
• Cyber incidents or attacks directed at the company could result in information theft, data corruption, operational disruption, and/or financial loss.

Future Outlook

The company intends to focus its search for business combination targets in the pharmaceutical industry, specifically aiming to mitigate U.S. medical supply chain risks by investing in companies that reduce reliance on foreign production. The strategic vision is to create a fully integrated, competitive cost business with end-to-end capabilities from plant-based raw material production to finished generic drugs, targeting an estimated $44 billion market segment. The company anticipates increased expenses as a public entity and may require additional financing (e.g., PIPE, debt) to complete a business combination or fund the growth of a target business.

Management Comments

• We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success.
• Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions.
• We will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders.
• We believe our management team is well positioned to take advantage of the growing set of investment opportunities focused on the pharmaceutical industry, and that our extensive existing relationships with portfolio companies along with our ongoing efforts to identify investment opportunities will allow us to generate an attractive transaction for our shareholders.
• We believe that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America's overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
• We believe that we have an important role in the future of the pharmaceutical business. With a successful series of target acquisitions the result will be a fully integrated competitive cost business with vast expertise.
• The aim will be for this business to have end-to-end capability from plant-based raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients (API)) to drug manufacturing and prescriptions filled by pharmacies or directly to the patients.
• The complete solution will aim to provide supply chain resilience while mitigating identified national health and security risks.
• Onboarding the production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America.

Industry Context

The company is entering the Special Purpose Acquisition Company (SPAC) market with a stated focus on the pharmaceutical industry. This aligns with broader national initiatives to strengthen the U.S. medical supply chain, as highlighted by the U.S. Senate Committee Homeland Security and Governmental Affairs' March 2023 findings on persistent critical medication shortages. The company aims to capitalize on the need for domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and generic drugs to reduce reliance on foreign sources. The filing acknowledges intense competition within the SPAC landscape for attractive targets, noting that many competitors possess greater resources and local industry knowledge.

Comparison to Industry Standards

• As a newly formed SPAC, the company has no operational history or financial results to compare against industry standards for operating companies.
• The company's investment criteria for target businesses (e.g., 'proven industry leader,' 'defensible and established business models,' 'sustainable financial profile') are aspirational and will be applied to future acquisitions, not current operations.
• The company acknowledges that the SPAC market is highly competitive, with many potential targets already acquired and numerous other SPACs seeking combinations, which could lead to increased costs or difficulty in securing a target.
• The company notes that many competitors in the SPAC space possess greater technical, human, and financial resources, potentially placing it at a competitive disadvantage in certain acquisition pursuits.

Management Changes

Corporate Governance

Legal Proceedings

• Lynn Stockwell, the company's CEO and Executive Chair, and John Stockwell, special advisor, are involved in ongoing litigation related to Bright Green Corporation (BGXX), a company founded by Lynn Stockwell. This includes a Chapter 11 bankruptcy proceeding filed by BGXX on February 22, 2025.
• In January 2021, BGXX filed a complaint against John Fikany, who counterclaimed against Lynn and John Stockwell alleging wrongful termination, fraud in the inducement, negligent misrepresentation, and breach of contract. In August 2024, a court determined an oral agreement for Mr. Fikany as CEO and that BGXX was not entitled to cancel his shares. BGXX plans to appeal this determination.
• A jury trial on Mr. Fikany's counterclaim for breach of employment contract was set for February 2025 but was vacated and has not been reset. BGXX plans to file motions opposing Mr. Fikany's claims in the Chapter 11 proceeding.

Related Party Transactions

• The sponsor, Drugs Made In America Acquisition II LLC (solely owned by Lynn Stockwell), purchased 14,375,000 founder shares for a nominal aggregate price of $35,000 (approximately $0.0024 per share).
• The sponsor and Cantor Fitzgerald & Co. committed to purchase an aggregate of 1,200,000 private units at $10.00 per unit ($12,000,000 total) in a private placement, with the sponsor purchasing 700,000 units.
• The sponsor has loaned the company up to $325,000 under an unsecured, non-interest bearing promissory note, with $297,292 outstanding as of June 30, 2025. This loan will be repaid from offering proceeds not held in the trust account.
• The company will pay the sponsor or an affiliate $10,000 per month for office space, administrative, and support services.
• The company's CFO, Glenn Worman, is a partner in an advisory firm that provides accounting services to the company, incurring $8,755 in expenses for the six months ended June 30, 2025.
• The sponsor, directors, officers, and their affiliates will be reimbursed for out-of-pocket expenses incurred in connection with identifying, investigating, and completing a business combination, with no stated cap.
• The sponsor or its affiliates/directors/officers may provide working capital loans up to $1,500,000, which may be convertible into private units at $10.00 per unit at the lender's option.
• The sponsor will transfer 100,000 founder shares to each officer and director nominee (excluding Lynn Stockwell) and 7,566,667 founder shares to unaffiliated accredited investors.
• John Stockwell, husband of CEO Lynn Stockwell, serves as an uncompensated special advisor, providing counsel on pharmaceutical investment strategies and regulatory considerations, but owes no fiduciary or contractual obligations regarding business opportunities to the company.

Stakeholder Impact

• **Public Shareholders**: Will experience significant immediate dilution (112.40%) due to the sponsor's low-cost founder shares. Their investment is speculative, with redemption rights at approximately $10.00 per share if no business combination is completed within 24 months, but rights will expire worthless. Their ability to influence business combination decisions is limited by the voting power of founder shares and potential non-vote redemptions. They face risks of reduced redemption value from third-party claims or negative interest rates, potential U.S. federal excise tax on redemptions, and liability for creditor claims.
• **Sponsor (Drugs Made In America Acquisition II LLC)**: Stands to gain substantial profit from its nominal investment in founder shares if a business combination is successful. It will lose its entire investment in founder shares and private units if no business combination is completed. The sponsor receives monthly administrative fees and reimbursement for expenses, and has provided a loan to the company.
• **Management and Directors**: Receive founder shares and may negotiate future compensation with a target business. They face significant conflicts of interest due to their simultaneous roles and fiduciary duties to another SPAC (DMAA), requiring them to present business opportunities to DMAA first. Some key personnel, including the CEO and special advisor, are involved in ongoing litigation and bankruptcy proceedings related to Bright Green Corp., which could negatively impact the company's reputation and management's focus.
• **Underwriters (Cantor Fitzgerald & Co.)**: Will receive upfront and deferred underwriting commissions, as well as private units. They may also provide additional services post-offering, creating potential conflicts of interest.
• **Potential Target Businesses**: Offered an alternative path to becoming a public company, with potential access to capital. However, they may face leverage from the SPAC due to the 24-month completion deadline and requirements for financial statement preparation.
• **Creditors**: Claims against the company could potentially reduce the funds available in the trust account for public shareholder redemptions, as their claims may have priority in a liquidation scenario.

Next Steps

• Commence the proposed sale of units to the public as soon as practicable after the effective date of the registration statement.
• Apply to list units on The Nasdaq Global Market (Nasdaq) under the symbol DMIIU on or promptly after the prospectus date.
• File a Current Report on Form 8-K with the SEC containing an audited balance sheet reflecting the receipt of gross proceeds from the offering.
• Ordinary shares and rights constituting the units will begin separate trading on the 52nd day following the prospectus date (or next business day), or earlier if Cantor Fitzgerald & Co. allows, subject to filing the Form 8-K and issuing a press release.
• Identify, acquire, and accelerate the growth of a company in the pharmaceutical industry within 24 months from the closing of the offering.
• Conduct in-depth due diligence on potential acquisition targets after negotiating and signing a letter of intent or preliminary agreement.
• Establish and maintain an audit committee and a compensation committee of the board of directors.
• Adopt a compensation recovery policy compliant with Nasdaq listing rules and a Code of Conduct for directors, officers, and employees.
• Assess the internal controls of the target business and implement/test additional controls as necessary to meet Sarbanes-Oxley Act requirements post-business combination.

Key Dates

Recommendation

The company is a newly formed SPAC with no operations or identified target, making it a speculative investment. While the management team has relevant industry experience and a clear strategy to address U.S. pharmaceutical supply chain issues, significant risks exist. These include substantial immediate dilution for public shareholders, potential conflicts of interest due to management's involvement in another SPAC, and the uncertainty of completing a suitable business combination within the 24-month timeframe. The potential for a U.S. federal excise tax on redemptions and the risk of being deemed a PFIC add further uncertainty. Investors should hold to monitor the progress of identifying a target and the terms of any proposed business combination, as well as how the company addresses its inherent conflicts and dilution.

Keywords

SPAC, Pharmaceutical Industry, IPO, Business Combination, SEC Filing, Blank Check Company, Cayman Islands, Trust Account, Redemption Rights, Founder Shares, Private Units, Corporate Governance, Supply Chain Resilience, Domestic Manufacturing, Active Pharmaceutical Ingredients, Generic Drugs, Lynn Stockwell, Glenn Worman, Cantor Fitzgerald, Dilution, Conflicts of Interest, S-1/A